SAM #HT9402-27-Q-9102

DHA Requests Quotes for Five Newly Approved Pharmaceutical Agents

The Defense Health Agency is seeking pharmaceutical quotations for five newly approved drugs for Department of War formulary review. - Government buyer: Defense Health Agency (DHA), Department of War (DoW); review by the DoW Pharmacy and Therapeutics Committee. No sub-agency or contracting office is specified. - Products requested: Atebrioz, Emcitate, Hibsago, Juvmo, and Zegfrovy. The notice gives no part numbers or purchase quantities. - Atebrioz: skeletal muscle relaxants and combinations. - Emcitate: thyroid and antithyroid agents. - Hibsago: hepatitis B agents. - Juvmo: Parkinson’s agents. - Zegfrovy: lung cancer, EGFR+ NSCLC subclass. - OEMs and vendors: No manufacturers, OEMs, or vendors are named in the notice. - Notable requirements: DHA is requesting quotations for formulary consideration. Quotations and responses to clinical questions are to follow the RFQ instructions. Formulary decisions may lead to Uniform Formulary agreements. - Value and performance period: No contract value, quantities, or performance period are provided.

Description

The Department of War (DoW) is required by law (10 U.S.C. § 1074g) to establish an effective, efficient, integrated pharmacy benefits program for the Military Health System (MHS) which includes the purchase pharmaceutical agents. The law and implementing regulation (32 CFR Section 199.21) describe the process by which the DoW Pharmacy and Therapeutics (P&T) Committee will consider the relative clinical effectiveness and relative cost effectiveness of pharmaceutical agents in a therapeutic class in recommending the selection of agents for the DoW Uniform Formulary (UF) and, for cost sharing purposes, the classification of a pharmaceutical agent as generic, formulary, Basic Core Formulary (BCF), Extended Core Formulary (ECF), or non-formulary (NF). Prior to the scheduled P&T Committee meeting, a Request for Quotation (RFQ) for pharmaceutical agents within Drug Classes identified for placement on the UF has been issued to obtain quotes from industry. The Defense Health Agency may award Uniform Formulary Blanket Purchase Agreements (UF BPA) and the Uniform Formulary Additional Discount Program Agreements (UF ADP) based on the UF decision. This process is described in the attached RFQ.

P&T COMMITTEE MEETING: The following February 2027 newly approved drugs will be reviewed:

Atebrioz – Skeletal Muscle Relaxants and Combinations – Subclass: NA Emcitate – Thyroid and Antithyroid Agents – Subclass: NA Hibsago – Hepatitis B Agents – Subclass: NA Juvmo – Parkinsons Agents – Subclass: NA Zegfrovy – Lung Cancer – Subclass: EGFR+ NSCLC

The RFQ, including UF BPA and UF ADP appendices, are attached herein. The instructions, important deadlines, and points of contact are in document, RFQ HT9402-27-Q-9102.

Pre-quotation teleconference is on November 17, 2026. Details are stated in Part 2.4. Pre-Quotation Teleconference. Responses to the clinical questions in Part 3.4 shall be submitted via e-mail to the RFQ POC in Part 2.3.1., no later than the date stated in Part 2.3.2.

Additional Links:https://health.mil/PandT

View original listing